The aberrant expression of PPARγ [51] is associated with NAFLD [52–54], and liver-specific loss of PPARγ is known to markedly attenuate the pathogenesis of NAFLD [55, 56]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.